Clinical Trials

Study data on forodesine in leukemia treatment presented at hematology meeting

Published in Cancer Weekly, December 13th, 2005

BioCryst Pharmaceuticals, Inc., (BCRX) announced that three abstracts related to the clinical development of Fodosine (forodesine hydrochloride), its lead product candidate for the treatment of certain leukemias and lymphomas, were published in Blood (Volume 106, Issue 11) and presented at the American Society of Hematology Annual Meeting in Atlanta, Georgia:

"Forodesine (Fodosine), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (phase II Study) (R. Furman et al.) was presented by Richard R. Furman of Cornell University, during the Poster Session. The poster includes an analysis of the phase II trial data demonstrating that intravenous...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry